ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock Price, Quote, News and Overview
NASDAQ:ADPT - Nasdaq - US00650F1093 - Common Stock - Currency: USD
ADPT Quote, Performance and Key Statistics
9.03
-0.24 (-2.59%)
The current stock price of ADPT is 9.03 USD. In the past month the price increased by 16.97%. In the past year, price increased by 158%.
ADPT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 18.41 | 152.18B | ||
| DHR | DANAHER CORP | 25.47 | 135.78B | ||
| A | AGILENT TECHNOLOGIES INC | 20.14 | 30.49B | ||
| IQV | IQVIA HOLDINGS INC | 13.18 | 26.27B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 26.72 | 22.53B | ||
| WAT | WATERS CORP | 28.89 | 20.47B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 32.09 | 15.31B | ||
| ILMN | ILLUMINA INC | 22.75 | 11.99B | ||
| ICLR | ICON PLC | 9.76 | 11.06B | ||
| RVTY | REVVITY INC | 18.51 | 10.96B | ||
| TEM | TEMPUS AI INC | N/A | 10.62B | ||
| QGEN | QIAGEN N.V. | 18.2 | 9.05B |
Related stock screener links
About ADPT
Company Profile
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 619 full-time employees. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Company Info
ADAPTIVE BIOTECHNOLOGIES
1165 Eastlake Ave E
Seattle WASHINGTON 98102 US
CEO: Chad Robins
Employees: 619
Phone: 12066590067
ADAPTIVE BIOTECHNOLOGIES / ADPT FAQ
What is the stock price of ADAPTIVE BIOTECHNOLOGIES today?
The current stock price of ADPT is 9.03 USD. The price decreased by -2.59% in the last trading session.
What is the ticker symbol for ADAPTIVE BIOTECHNOLOGIES stock?
The exchange symbol of ADAPTIVE BIOTECHNOLOGIES is ADPT and it is listed on the Nasdaq exchange.
On which exchange is ADPT stock listed?
ADPT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ADAPTIVE BIOTECHNOLOGIES stock?
14 analysts have analysed ADPT and the average price target is 11.56 USD. This implies a price increase of 28.02% is expected in the next year compared to the current price of 9.03. Check the ADAPTIVE BIOTECHNOLOGIES stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADAPTIVE BIOTECHNOLOGIES worth?
ADAPTIVE BIOTECHNOLOGIES (ADPT) has a market capitalization of 1.37B USD. This makes ADPT a Small Cap stock.
How many employees does ADAPTIVE BIOTECHNOLOGIES have?
ADAPTIVE BIOTECHNOLOGIES (ADPT) currently has 619 employees.
What are the support and resistance levels for ADAPTIVE BIOTECHNOLOGIES (ADPT) stock?
ADAPTIVE BIOTECHNOLOGIES (ADPT) has a support level at 7.17. Check the full technical report for a detailed analysis of ADPT support and resistance levels.
Is ADAPTIVE BIOTECHNOLOGIES (ADPT) expected to grow?
The Revenue of ADAPTIVE BIOTECHNOLOGIES (ADPT) is expected to grow by 22.96% in the next year. Check the estimates tab for more information on the ADPT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ADAPTIVE BIOTECHNOLOGIES (ADPT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ADPT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ADPT, evaluating the profitability, health, valuation and growth aspects
- ADAPTIVE BIOTECHNOLOGIES (ADPT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADAPTIVE BIOTECHNOLOGIES (ADPT) Sales and EPS estimates to see what analysts future expectations are.
- ADAPTIVE BIOTECHNOLOGIES (ADPT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADAPTIVE BIOTECHNOLOGIES (ADPT) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock Chart to make your own analysis
- ADAPTIVE BIOTECHNOLOGIES (ADPT) Latest news and press-releases to stay up to date.
Does ADAPTIVE BIOTECHNOLOGIES (ADPT) stock pay dividends?
ADPT does not pay a dividend.
When does ADAPTIVE BIOTECHNOLOGIES (ADPT) report earnings?
ADAPTIVE BIOTECHNOLOGIES (ADPT) will report earnings on 2025-07-30, after the market close.
What is the Price/Earnings (PE) ratio of ADAPTIVE BIOTECHNOLOGIES (ADPT)?
ADAPTIVE BIOTECHNOLOGIES (ADPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.96).
What is the Short Interest ratio of ADAPTIVE BIOTECHNOLOGIES (ADPT) stock?
The outstanding short interest for ADAPTIVE BIOTECHNOLOGIES (ADPT) is 6.88% of its float. Check the ownership tab for more information on the ADPT short interest.
ADPT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ADPT. When comparing the yearly performance of all stocks, ADPT is one of the better performing stocks in the market, outperforming 98.12% of all stocks.
ADPT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADPT. ADPT has a bad profitability rating. Also its financial health evaluation is rather negative.
ADPT Financial Highlights
Over the last trailing twelve months ADPT reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS increased by 26.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.76% | ||
| ROE | -74.49% | ||
| Debt/Equity | 0.69 |
ADPT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ADPT. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 13.67% and a revenue growth 22.96% for ADPT